CATX

#3152
Perspective Therapeutics, Inc. Common Stock
3.1 5 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.11
3.24
Jahresspanne
1.96
6.16
Tagesänderung
-0.95%
Monatliche Änderung
+8.25%
6 month change
-37.25%
Jahresänderung
-5.12%
Vorheriger Schlusskurs
3.1 2
Open
3.1 1
Tief
3.1 1
Hoch
3.2 4
Volumen
148
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Perspective Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K

Perspective Therapeutics, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Company: Perspective Therapeutics, Inc. (NYSE American: CATX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2025
Reporting Period: The filing announces financial results for the year ended December 31, 2024, and provides recent business highlights.

Key Financial Metrics

The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:

  • Revenue: Not provided in filing text.
  • Profit/Loss: Not provided in filing text.
  • Cash Flow: Not provided in filing text.
  • Margins: Not provided in filing text.
  • Debt and Liquidity: Not provided in filing text.

Material Changes

The filing text does not detail specific material changes or comparative financial data versus prior periods. It serves only to notify investors that results for the year ended December 31, 2024, have been issued via a press release.

Guidance, Outlook, and Management Commentary

Management Commentary: The Company issued a press release on March 26, 2025, containing financial results and business highlights. Additionally, an updated corporate presentation was posted to the Company's website.
Guidance and Risks: No specific forward-looking guidance, risk factors, or contingencies are detailed in the provided text. These items are likely contained within the referenced Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2024.
  • Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline progress, and liquidity runway.
  • Verify the Company's cash burn rate and funding requirements as detailed in the full press release.
  • Confirm any new strategic partnerships or regulatory milestones mentioned in the "business highlights" section of the press release.

Nachrichten